Samuel J Reich
CIK 1394645 · CEO · last filed 2026-02-05
Samuel J Reich is a CEO who has filed 14 SEC Form 4 insider transactions across 3 companies since 2021. The most recent filing, for SABSW, was dated Feb 5, 2026. Across all open-market trades the lifetime net is +$4.2M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $843 across reported positions. 2 SEC filings were submitted jointly with OPKO HEALTH, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BCYPU price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3701 MARKET STREET
PHILADELPHIA, PA 19104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SABSW | CEO | 766,699 | $0.00 | $843 | $9.8K | 11 | 2026-02-05 |
| SAB Biotherapeutics, Inc. (BCYPW) Delisted | CEO and CFO | 3,048,825 | $1.10 | $3.35M | $10.1K | 1 | 2021-10-15 |
| SAB Biotherapeutics, Inc. (BCYPU) Delisted | CEO and CFO | 3,047,825 | $8.57 | $26.12M | $4.17M | 1 | 2021-01-14 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-05 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2025-08-28 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2024-02-23 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2023-11-30 | SABSW | Buy (P) | +11,000 | $9.8K | EDGAR |
| 2023-03-16 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2023-03-02 | SABSW | Other (J) | — | $0 | EDGAR |
| 2022-09-15 | SABSW | Grant (A) | — | $0 | EDGAR |
| 2022-05-23 | SABSW | Other (J) | −2,293,126 | $0 | EDGAR |
| 2022-03-18 | SABSW | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.